Meeting abstract
https://doi.org/10.33004/reumatizam-supp-71-1-20
Combination of rituximab and tofacitinib IN THE TREATMENT of anti-MDA 5 antibody positive dermatomyositis – case reports
Filip Mirić
*
Srđan Novak
* Corresponding author.
Full text: croatian pdf 650 Kb
page 22-23
downloads: 52
cite
APA 6th Edition
Mirić, F. & Novak, S. (2024). Combination of rituximab and tofacitinib IN THE TREATMENT of anti-MDA 5 antibody positive dermatomyositis – case reports. Reumatizam, 71 (Supp 1). https://doi.org/10.33004/reumatizam-supp-71-1-20
MLA 8th Edition
Mirić, Filip and Srđan Novak. "Combination of rituximab and tofacitinib IN THE TREATMENT of anti-MDA 5 antibody positive dermatomyositis – case reports." Reumatizam, vol. 71, no. Supp 1, 2024 https://doi.org/10.33004/reumatizam-supp-71-1-20. Accessed 27 Dec. 2024.
Chicago 17th Edition
Mirić, Filip and Srđan Novak. "Combination of rituximab and tofacitinib IN THE TREATMENT of anti-MDA 5 antibody positive dermatomyositis – case reports." Reumatizam 71, no. Supp 1 https://doi.org/10.33004/reumatizam-supp-71-1-20
Harvard
Mirić, F., and Novak, S. (2024). 'Combination of rituximab and tofacitinib IN THE TREATMENT of anti-MDA 5 antibody positive dermatomyositis – case reports', Reumatizam, 71(Supp 1). https://doi.org/10.33004/reumatizam-supp-71-1-20
Vancouver
Mirić F, Novak S. Combination of rituximab and tofacitinib IN THE TREATMENT of anti-MDA 5 antibody positive dermatomyositis – case reports. Reumatizam [Internet]. 2024 [cited 2024 December 27];71(Supp 1). https://doi.org/10.33004/reumatizam-supp-71-1-20
IEEE
F. Mirić and S. Novak, "Combination of rituximab and tofacitinib IN THE TREATMENT of anti-MDA 5 antibody positive dermatomyositis – case reports", Reumatizam, vol.71, no. Supp 1, 2024. [Online]. https://doi.org/10.33004/reumatizam-supp-71-1-20
Abstract
Keywords
Hrčak ID:
322089
URI
https://hrcak.srce.hr/322089
Publication date:
24.10.2024.
Article data in other languages:
croatian
Visits: 128
*